All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease occurring in 2--5 per 1000 individuals, and is caused by mutations in genes encoding sarcomeric proteins.\[[@pone.0232427.ref001]--[@pone.0232427.ref003]\] The defining feature of HCM is unexplained left ventricular (LV) hypertrophy that mainly affects the interventricular septum (IVS). In addition to hypertrophy, the diseased myocardium is characterized by increased interstitial fibrosis, myofibrillar and cardiomyocyte disarray and vascular abnormalities.\[[@pone.0232427.ref004],[@pone.0232427.ref005]\] Clinical symptoms generally appear between 20--50 years of age and can range from shortness of breath to atrial fibrillation. In the majority of patients, these symptoms can be managed with therapy, and individuals have a normal life expectancy.\[[@pone.0232427.ref006]\] However, a subset of patients suffers from life-threatening complications such as sudden cardiac arrest at a young age or progresses to end-stage heart failure.\[[@pone.0232427.ref006]\]

To classify the different forms of HCM, *Olivotto et al*.\[[@pone.0232427.ref007]\] described different stages in cardiac disease progression ranging from unaffected mutation carriers to end-stage failing HCM patients.\[[@pone.0232427.ref008]\] The majority of HCM patients develop a 'classic' (stage II) form of HCM with the characteristic septal thickening, LV outflow tract obstruction (LVOTO) and diastolic dysfunction. Approximately 5--10% of all HCM patients progress to the severe end-stage of HCM (stage IV), which is characterized by thinning of the IVS and LV wall, and left atrial dilation, extensive fibrosis and impaired systolic function. These patients show a decrease in NYHA classification and are often diagnosed with or develop atrial fibrillation.\[[@pone.0232427.ref009]\] The progression from the 'classic' stage of HCM, via adverse remodeling (stage III) to stage IV shows a relatively short clinical course of approximately 6.5 years.\[[@pone.0232427.ref010]\] It is unclear which factors underlie the transition from a stable stage II to stage IV of HCM in a relatively small but severely ill group of patients.

Notably, the lifetime risk of heart failure is higher in women than in men.\[[@pone.0232427.ref011]\] At first evaluation, female HCM patients are older and present more often with symptoms.\[[@pone.0232427.ref012],[@pone.0232427.ref013]\] Moreover, women show a higher risk of progression to heart failure (stage IV).\[[@pone.0232427.ref012],[@pone.0232427.ref014]\] We recently showed more severe diastolic dysfunction in female compared to male HCM patients at the time of myectomy (stage II), which coincided with more advanced tissue remodeling in women compared to men.\[[@pone.0232427.ref015]\] Here we investigated if differences in functional and structural properties of the heart may underlie sex-differences in disease progression from stage II to IV of HCM. Functional measurements in single cardiomyocytes were combined with analyses of protein expression, fibrosis and capillary density.

Methods {#sec002}
=======

Myocardial samples {#sec003}
------------------

Cardiac samples were collected from 54 patients with obstructive HCM (stage II) (44% female) carrying a *MYH7* (myosin heavy chain; n = 14) or a *MYBPC3* (myosin-binding protein-C; n = 40) mutation (stage II) and 10 end-stage (stage IV) patients (40% female) carrying a *MYH7* (n = 6), a *MYBPC3* (n = 3) or a *TNNT2* (troponin T; n = 1) mutation. [Fig 1A](#pone.0232427.g001){ref-type="fig"} illustrates the different gene mutations and [Fig 1B](#pone.0232427.g001){ref-type="fig"} shows where mutations are located in the protein. [Table 1](#pone.0232427.t001){ref-type="table"} provides an overview of the gene mutations of all patients. Patient samples were compared with non-failing control samples (n = 30; 40±14 years; 43% female; [S1 Table](#pone.0232427.s001){ref-type="supplementary-material"}) without a history of cardiac abnormalities. IVS tissue from the stage II HCM group was collected during myectomy to relieve LVOTO. Cardiac tissue from stage IV HCM was obtained during heart transplantation surgery and consisted of IVS (n = 6) and LV tissue (n = 4). Control samples included IVS (n = 3) and LV (n = 27) tissue. All samples were immediately frozen and stored in liquid nitrogen. This study was approved by the local ethics board of the Erasmus Medical Center (protocol number MEC-2010-40) and written informed consent of patients was obtained. Non-failing donor samples were acquired from the University of Sydney, Australia, with the ethical approval of the Human Research Ethics Committee (\#2012/2814). We acknowledge the uneven distribution between patient numbers and mutations and tissue locations (IVS and LV). However, our tissue characterization was dependent on available cardiac tissue and clinical parameters. Due to limited tissue availability, not all analyses could be performed in all patient/control samples.

![A. Mutations present in the patient samples. Mutations of patients that were included in this study. Myosin heavy chain gene (*MYH7*) mutations are depicted in blue squares of which two mutations (R719W and R403Q) were present in both stage II and IV (end-stage) HCM patient groups. Myosin-binding protein~~-~~C gene (*MYBPC3*) mutations are depicted in the yellow squares of which one mutation (E258K) was present in both HCM patient groups. The three Dutch founder mutations are depicted in the dotted squares. The troponin T gene (*TNNT2*) mutation is depicted in the green square and was only present in the end-stage patient group. Color tone indicates the number of patients carrying the specific mutation, with the darkest tone representing most patients (patient details are given in [Table 1](#pone.0232427.t001){ref-type="table"}). B. Mutation location. Schematic of 3 main HCM sarcomere proteins: myosin heavy chain in green (Myosin), cardiac myosin-binding protein-C in purple (cMyBP-C) and cardiac troponin T in orange (cTnT). The location of the mutations is indicated with the blue circles (M). The letters N and C stand for the N-terminus and C-terminus respectively. The numbers indicate the amino acids of the sarcomere proteins.](pone.0232427.g001){#pone.0232427.g001}

10.1371/journal.pone.0232427.t001

###### Patient information and gene mutations.

![](pone.0232427.t001){#pone.0232427.t001g}

  Sample code         SEX   AGE (Y)   GENE       MUTATION CODE   DOMAIN & INFO   IVS (mm)   IVSi       LAD         LADi        LVEDD      LVEDDi     LVOTO       E/A RATIO      E WAVE    TR VELOCITY   DRUG REGIMEN
  ------------------- ----- --------- ---------- --------------- --------------- ---------- ---------- ----------- ----------- ---------- ---------- ----------- -------------- --------- ------------- ------------------------------
  **STAGE II**                                                                                                                                                                                          
  **HCM 2**           F     32        *MYBPC3*   Y842L           C6 / DF         30         20         *-*         \-          40         27         \-          \-             \-        0.3           Bb
  **HCM 3**           F     39        *MYPBC3*   Y842L           C6 / DF         20         11         40          23          38         21         49          \-             0.8       \-            Ccb, diuretics
  **HCM 4**           F     44        *MYBPC3*   Y842L           C6 / DF         20         13         45          30          40         27         94          \-             0.8       \-            Ccb
  **HCM 5**           F     41        *MYBPC3*   c.1458-1G\>C    Intr 16         22         13         46          27          37         21         92          3.8            1.1       \-            Bb, ccb
  **HCM 7**           F     44        *MYBPC3*   Y842L           C6 / DF         17         11         40          25          42         26                     \-             \-        \-            Ccb
  **HCM 26**          F     57        *MYBPC3*   Y842L           C6 / DF         24         11         62          28          41         18         74          0.7            0.4       \-            Bb
  **HCM 34**          F     47        *MYBPC3*   R597Q           C4              20         10         46          23          42         21         38          2              0.9       3             Bb, ccb, statin
  **HCM 35**          F     65        *MYBPC3*   A536A           C3              19         \-         \-          \-          45         \-         18          \-             \-        2.7           Bb, ccb
  **HCM 52**          F     24        *MYBPC3*   R943x           C7 / DF         24         14         44          26          35         20         34          1.12           0.9       2.5           Bb
  **HCM 60**          F     45        *MYBPC3*   c.3029delA      C8              18         9          46          24          42         22         125         0.68           0.6       1.9           Bb, ccb
  **HCM 94**          F     66        *MYBPC3*   E611K           C4              15         8          53          27          43         22         55          \-             \-        2             Bb, ccb, ACE, statin, oac
  **HCM 113**         F     21        *MYBPC3*   R943x           C7 / DF         45         28         43          26          40         25         27          1.26           0.7       2.3           Bb, ccb
  **HCM 116**         F     53        *MYBPC3*   R943x           C7 / DF         \-         \-         \-          \-          \-         \-         \-          \-             \-        \-            \-
  **HCM 121**         F     54        *MYBPC3*   Q1259R          C10             20         12         33          21          37         23         45          0.93           1         1.5           Ccb
  **HCM 123**         F     59        *MYBPC3*   Y842L           C6 / DF         21         \-         45          \-          55         \-         64          1.2            1.4       3.1           Bb, ccb, oac, ACE, Diuretics
  **HCM 180**         F     51        *MYBPC3*   Y340x           MM              32         \-         \-          \-          45         \-         70          2.25           0.9       \-            Bb
  **HCM 148**         F     51        *MYBPC3*   G531R           C3              20         9          58          26          51         23         56          0.97           0.7       \-            \-
  **HCM 150**         F     57        *MYBPC3*   P699Q           C5              24         12         49          25          50         26         68          2.5            1.3       \-            \-
  **HCM 12**          M     37        *MYBPC3*   c.927-2A\>G     Intr 11         19         9          41          20          42         21         44          2              1         \-            Bb
  **HCM 33**          M     48        *MYBPC3*   c.927-2A\>G     Intr 11         \-         \-         \-          \-          \-         \-         82          \-             \-        \-            Bb
  **HCM 36**          M     22        *MYBPC3*   c.927-2A\>G     Intr 11         30         \-         60          \-          44         \-         71          0.73           0.4       \-            Bb, ccb
  **HCM 42**          M     32        *MYBPC3*   Y842L           C6 / DF         23         13         47          26          43         24         64          1.03           0.7       \-            Bb, ccb
  **HCM 43**          M     60        *MYBPC3*   Y842L           C6 / DF         23         \-         52          \-          45         \-         77          2              0.8       \-            Bb, ccb
  **HCM 47**          M     55        *MYBPC3*   Y1136d          C9              25         13         \-          \-          40         21         96          1.57           1         2.9           Ccb
  **HCM 62**          M     36        *MYBPC3*   E258K           MM              27         14         37          19          32         16         \-          1.21           0.4       1.8           Bb, ACE, diuretics
  **HCM 63**          M     33        *MYBPC3*   R943x           C7 / DF         21         12         40          22          46         26         25          2.38           1.1       \-            Bb, ccb
  **HCM 66**          M     45        *MYBPC3*   Q1259R          C10             \-         \-         \-          \-          \-         \-         \-          \-             \-        \-            \-
  **HCM 71**          M     49        *MYBPC3*   R943x           C7 / DF         16         7          47          22          44         20         \-          0.78           0.5       2.3           Bb
  **HCM 82**          M     71        *MYBPC3*   S928L           C7              20         11         52          29          49         28         64          0.87           0.7       2.2           Bb, oac
  **HCM 83**          M     17        *MYBPC3*   Y842L           C6 / DF         \-         \-         \-          \-          \-         \-         \-          \-             \-        \-            \-
  **HCM 101**         M     20        *MYBPC3*   c.1458-1G\>C    Intr 16         38         17         42          19          \-         \-         \-          1.25           0.5       \-            Bb
  **HCM 103**         M     26        *MYBPC3*   Y842L           C6 / DF         20         9          47          22          47         22         13          1.33           0.7       1.4           Bb
  **HCM 104**         M     33        *MYBPC3*   Y842L           C6 / DF         24         13         33          18          40         22         31          1.08           0.6       \-            Bb
  **HCM 110**         M     39        *MYBPC3*   E334x           MM              18         8          \-          \-          46         21         9           2.48           0.8       2.4           Ccb
  **HCM 120**         M     27        *MYBPC3*   Y842L           C6 / DF         24         13         39          21          37         20         61          1.42           0.8       2.3           Bb
  **HCM 122**         M     50        *MYBPC3*   c.3331-2A\>G    Intr 30         22         10         \-          \-          45         21         58          0.67           0.7       2.5           Bb, ccb
  **HCM 124**         M     53        *MYBPC3*   R943x           C7 / DF         21         10         43          21          47         23         41          0.64           0.5       2.2           Bb
  **HCM 133**         M     58        *MYBPC3*   G148R           PA              21         10         44          21          40         19         19          0.86           0.6       2.4           Bb, statin, oac
  **HCM 141**         M     46        *MYBPC3*   E258K           MM              23         \-         51          \-          51         \-         20          1.22           0.7       \-            Bb
  **HCM 149**         M     46        *MYBPC3*   E258K           MM              26         \-         *-*         \-          \-         \-         72          \-             \-        \-            \-
  **HCM 27**          F     58        *MYH7*     T1377M          MT              20         13         48          30          \-         \-         100         \-             0.6       2.8           Bb
  **HCM 42B**         F     46        *MYH7*     V606M           MH              20         9          51          24          \-         \-         77          3.38           0.8       2.6           Bb, ccb
  **HCM 157**         F     65        *MYH7*     S1843C          MT              22         10         58          27          42         20          -          2.37           1.9       3.3           Ccb, statin
  **HCM 166**         F     66        *MYH7*     R694C           MH              16         \-         41          \-          \-         \-         41          0.79           1.1       \-            Bb, ccb, ASA
  **HCM 144**         F     30        *MYH7*     S782R           Hinge           29         \-         *-*         \-          42         \-         128         \-             \-        \-            \-
  **HCM 154**         F     6         *MYH7*     R719W           MH / Fam I      20         26         *-*         \-          \-         \-         46          \-             \-        \-            \-
  **HCM 32**          M     43        *MYH7*     T1377M          MT              21         9          51          21          47         19         121         1              0.6       \-            Bb, diuretics
  **HCM 80**          M     34        *MYH7*     c.1291G\>C      MT              17         8          \-          \-          45         21         85          1.45           0.9       1.4           Bb, ccb
  **HCM 106**         M     35        *MYH7*     D928V           MT              16         8          \-          \-          47         24         16          0.93           0.8       2.1           Bb
  **HCM 114**         M     69        *MYH7*     A326P           MH              19         \-         43          \-          33         \-         71          0.6            0.6       2.1           Bb, statin, ASA
  **HCM 119**         M     41        *MYH7*     E1233K          MT              20         9          56          26          \-         \-         81          1.26           1.1       1.4           Bb
  **HCM 130**         M     45        *MYH7*     A326P           MH              18         9          42          21          50         25         27          2.6            1.3       3.3           Bb, statin, noac
  **HCM 145**         M     28        *MYH7*     R694C           MH              42         \-         52          \-          38         \-         30          1.5            0.6       \-            Bb
  **HCM 143**         M     26        *MYH7*     R403Q           MH              34         \-         *-*         \-          50         \-         85          \-             \-        \-            \-
  **MEAN STAGE II**                                                              **23±6**   **12±4**   **47±7**    **24±3**    **43±5**   **22±3**   **59±30**   **1.75±0.5**   **1±0**   **2.5±0.7**   
  **STAGE IV**                                                                                                                                                                                          
  **HCM 147**         F     36        *MYBPC3*   P955R           C7 / DF         \-         \-         *-*         \-          75         \-         \-          \-             \-        \-            \-
  **HCM 142**         M     46        *MYPBC3*   E258K + E441K   MM + C2         18         \-         51          \-          50         \-         5           \-             \-        \-            Bb, ACE, diuretics
  **HCM 137**         M     54        *MYBPC3*   Y842L           C6              \-         \-         \-          \-          60         \-         \-          \-             \-        \-            \-
  **HCM 183**         F     39        *MYH7*     R453C           MH              \-         \-         *-*         \-          54         31         10          \-             \-        \-            \-
  **HCM 151**         F     59        *MYH7*     R403Q           MH              \-         \-         70          50          53         38         10          \-             \-        \-            \-
  **HCM 181**         F     40        *MYH7*     R719W           MH / Fam I      18         10         48          27          54         31         \-          \-             \-        \-            \-
  **HCM 152**         M     35        *MYH7*     R403Q           MH              \-         \-         *-*         \-          \-         \-         \-          \-             \-        \-            \-
  **HCM 153**         M     49        *MYH7*     R719W           MH / Fam I      16         9          52          29          50         28         \-          \-             \-        \-            \-
  **HCM 139**         M     61        *MYH7*     R787H           Hinge           \-         \-         *-*         \-          58         \-         \-          \-             \-        \-            \-
  **HCM 140A**        M     26        *TNNT2*    K280N           C-terminus      \-         \-         *-*         \-          \-         \-         \-          \-             \-        \-            \-
  **MEAN STAGE IV**                                                              **17±1**   **10+1**   **55+10**   **35+13**   **57±8**   **32±4**   **8±3**                                            

Abbreviations: F, female; M, male; sarcomere genes *MYBPC3*, *MYH7* and *TNNT2* encoding myosin-binding protein-C, myosin heavy chain and cardiac troponin T, respectively. Domain & info: DF: Dutch founder mutation; Fam I: patient samples part of one family. Domain locations of the mutations (also illustrated in [Fig 1B](#pone.0232427.g001){ref-type="fig"}): MM: cMyBP-C motif (in [Fig 1B](#pone.0232427.g001){ref-type="fig"} depicted as yellow stripes between C1-C2); PA: Pro-Ala rich region (in [Fig 1B](#pone.0232427.g001){ref-type="fig"} depicted as grey stripes between C0-C1); MT: Myosin tail (in [Fig 1B](#pone.0232427.g001){ref-type="fig"} the dark green line); MH: Myosin head; Hinge: hinge region of myosin (in [Fig 1B](#pone.0232427.g001){ref-type="fig"} depicted as the curled green line); IVS, interventricular septum; IVSi, IVS indexed by body surface area (BSA); LAD, left atrial diameter; LADi, LAD indexed by BSA; LVEDD, left ventricular end-diastolic diameter; LVEDDi indexed by BSA; LVOTO, left ventricular outflow tract obstruction; E/A ratio, ratio of mitral valve early (E) and late (A) velocity; E wave, mitral valve early velocity (cm/s); TR velocity, tricuspid regurgitation velocity (m/s); bb, betablocker; ccb, calcium channel blocker; ACE, ACE-inhibitor; (N)OAC, (novel) oral anticoagulant; ASA, antiplatelet therapy (acetylsalicylic acid).

Echocardiographic measurements {#sec004}
------------------------------

Echocardiographic studies were done with commercially available systems and analyzed according to the American Society of Echocardiography guidelines.\[[@pone.0232427.ref016]\] Maximal wall thickness, left atrial diameter (LAD), LV end-diastolic diameter (LVEDD), and LVOTO gradient were measured. LVOTO was defined as a gradient ≥ 30 mmHg at rest or during provocation. Mitral valve inflow was recorded using pulsed wave Doppler from the apical four chamber view. Mitral E and A velocity (cm/s) and deceleration time (ms) were measured. Pulsed wave tissue Doppler imaging was used to measure septal e' velocity (cm/s). Continuous wave Doppler in the parasternal and apical four chamber was used to measure tricuspid regurgitation (TR) velocity (m/s). Echocardiographic data and medication are shown in [Table 1](#pone.0232427.t001){ref-type="table"}. For the end-stage HCM group, a limited set of echocardiographic data was obtained, and not all parameters were obtained for stage II patients.

Diastolic dysfunction was graded as follows: grade I when E/A ratio ≤ 0.8 and E peak velocity ≤ 50 cm/s; grade III when E/A ratio ≥ 2. In patients with E/A ratio ≤ 0.8 and E peak velocity \> 50 cm/s or E/A ratio \> 0.8 but \< 2, the E/e' ratio (\>14), LADi (\>24) and TR velocity (\> 2.8 m/s) were used to further differentiate diastolic function. When ≥ 2 out of 3 variables were abnormal, LA pressure was elevated and grade II diastolic dysfunction was present. When 1 out of 3 variables was abnormal, grade I diastolic dysfunction was present.\[[@pone.0232427.ref017]\]

Isometric force measurements {#sec005}
----------------------------

Force measurements were performed in mechanically isolated single, membrane-permeabilized, cardiomyocytes as described previously.\[[@pone.0232427.ref018],[@pone.0232427.ref019]\] In short, we measured passive tension at a range of sarcomere lengths (SL)(1.8--2.4 μm). All passive forces were normalized to cardiomyocyte cross-sectional area (CSA) (i.e. CSA = width x depth x π/4). Active tension (maximal force) was measured at SL 2.2 μm, and we determined myofilament calcium sensitivity (EC~50~) by activating cardiomyocytes in solutions with different calcium concentrations.

Protein analyses {#sec006}
----------------

Titin isoform gel electrophoresis was performed as previously described.\[[@pone.0232427.ref019],[@pone.0232427.ref020]\] Samples were measured in triplicate, of which the mean was used.

Histomorphometrical analyses {#sec007}
----------------------------

Cardiomyocyte myofibril density (MFD) was measured using Electron Microscopy (EM) as described previously.\[[@pone.0232427.ref021]\] MFD was calculated by the sum of myofibril area relative to the total cardiomyocyte area and expressed as a percentage.\[[@pone.0232427.ref021],[@pone.0232427.ref022]\] To determine the extent of interstitial and replacement fibrosis, cryosections were stained using Picro-Sirius Red, and fibrosis was expressed as collagen volume fraction (CVF%). Capillary density was determined by the number of capillaries per mm^2^ and per cardiomyocyte. Cryosections were incubated with a primary antibody (Monoclonal Mouse anti-Human CD31, Endothelial cell; Clone JC70A; DAKO; REF M0823) and secondary antibody (EnVision HRP α-mouse/rabbit (DAKO). Staining was visualized using 3.3'-diaminobenzidine (0.1 mg/mL, 0.02% H~2~O~2~), the sections were subsequently counterstained with hematoxylin.

Data analyses {#sec008}
-------------

Data in figures are presented as mean±standard error of the mean per group, data in tables is presented as mean±standard deviation. If data was normally distributed means were compared with a student's T-test, a Mann-Whitney test was used when data was not normally distributed. Sex-differences were tested with a 2-way ANOVA. P\<0.05 was considered significant, differences to controls are indicated by an asterisk (\*), sex-differences are indicated by a hashtag (\#).

Results {#sec009}
=======

A *MYBPC3* gene mutation was present in 43 patients (40 stage II and 3 stage IV), of which 18 were founder mutations. Most *MYH7* mutations were located in the myosin head (60%) ([Fig 1B](#pone.0232427.g001){ref-type="fig"} and [Table 1](#pone.0232427.t001){ref-type="table"}). Average values for echocardiographic characteristics of HCM stage II and IV patients are shown in [Table 2](#pone.0232427.t002){ref-type="table"}. HCM stage II and IV patients have a similar average age and male patients are dominant in both groups. All patients meet the diagnostic criteria of an IVS thickness \> 15 mm ([Table 1](#pone.0232427.t001){ref-type="table"}), however, the HCM stage II patients show significantly greater septal thickness than the HCM stage IV patients. This is in line with a higher LVOTO in the stage II compared to stage IV HCM. LAD and LVEDD were significantly higher in stage IV compared to stage II HCM.\[[@pone.0232427.ref023]\] All stage IV patients were given grade III diastolic dysfunction, while stage II patients included 29% with grade III, 29% with grade II and 42% with grade I diastolic dysfunction. Female stage II patients show more severe diastolic dysfunction compared to male patients: 86% grade II or III diastolic dysfunction in women compared to 42% grade II in men. Drug regimen was different between female and male stage II HCM patients: 80% of the men received betablockers in contrast to 58% of the women. Calcium channel blockers were prescribed more frequently to women compared to men (58% versus 27%, respectively; [Table 1](#pone.0232427.t001){ref-type="table"}). Unfortunately we could only retrieve drug regimen of one of our stage IV patients.

10.1371/journal.pone.0232427.t002

###### Clinical characteristics of HCM stage II and IV patient groups.

![](pone.0232427.t002){#pone.0232427.t002g}

                 stage II    stage IV    P
  -------------- ----------- ----------- --------------
  N (% female)   54 (44%)    10 (40%)    
  Age (years)    43.4±14.7   44.5±11.3   0.83
  IVS (mm)       22.9±6.3    17.3±1.2    **\<0.05**
  LVOTO (mmHG)   59.2±30.4   8.3±2.9     **\<0.001**
  LAD (mm)       46.5±6.9    55.3±10.0   **\<0.05**
  LVEDD (mm)     43.1±5.0    56.8±8.2    **\<0.0001**

Abbreviations: IVS (interventricular septum); LAD (left atrial dimension); LVEDD (left ventricular end-diastolic dimension); LVOTO (left ventricular outflow tract obstruction).

Maximal force generating capacity (Fmax) of cardiomyocytes was significantly lower in stage II and IV HCM compared to controls (21.8±1.7 and 19.6±2.3 versus 32.8±2.9 KN/m^2^ respectively; p\<0.01), but did not differ between patient groups or sex ([Fig 2A](#pone.0232427.g002){ref-type="fig"}). Passive tension (Fpass) was lower in both stage II and IV HCM compared to controls ([Fig 2B](#pone.0232427.g002){ref-type="fig"}; p\<0.0001). No sex-differences in passive tension were observed. [Fig 2C](#pone.0232427.g002){ref-type="fig"} shows representative images of myofibril density analyses by EM (stage II and IV HCM patient samples). Both HCM groups showed a similar decrease in MFD compared to controls (p\<0.0001), while no sex-difference was observed ([Fig 2D](#pone.0232427.g002){ref-type="fig"}). Compared to controls, a significantly higher myofilament calcium-sensitivity was found in both stage II and IV HCM (EC~50~: 2.2±0.1 μmol/L and 3.0±0.2 versus 2.0±0.1 respectively; p\<0.001), with no difference between the HCM groups or sex ([Fig 2E](#pone.0232427.g002){ref-type="fig"}).

![Cardiomyocyte properties--no differences between stage II and IV HCM patients.\
A) Maximal force development is lower in stage II (n = 26) and stage IV (n = 8) patients in comparison to controls (p\<0.0001) and no sex-differences were found. B) Passive tension is lower in stage II (n = 19) and stage IV (n = 8) patients in comparison to controls (p\<0.0001, no sex-differences were found). C and D) Electron Microscopy (EM) imaging was performed and showed reduced myofibril density in stage II and IV HCM patient samples compared to controls. No sex-difference was present in myofibril density. E) Myofilament calcium-sensitivity is depicted as EC~50~ (the amount of calcium needed to reach 50% of maximal force). EC~50~ is significantly lower in stage II and IV HCM patients compared to controls (p\<0.001). No sex-differences were found. Controls used for passive tension: 1, 12--13, 20; maximal force development: 5--8, 11--12, 15--16, 18--19, 23, 26; myofilament calcium-sensitivity: 5--8, 11--12, 15--16, 18--19, 23.](pone.0232427.g002){#pone.0232427.g002}

The N2BA/N2B titin isoform ratio was significantly higher in both HCM groups compared to controls, without a difference between stage II and IV HCM (0.84±0.05 versus 0.81±0.12). At both HCM disease stages females show a higher N2BA/N2B ratio compared to males ([Fig 3A](#pone.0232427.g003){ref-type="fig"}). Analysis of fibrosis showed increased fibrosis in stage II and IV HCM patients compared to controls (4.6±0.5 and 5.5±0.9 versus 1.2±0.2% respectively; p\<0.001). Representative Picro-Sirius red staining images of stage II and IV HCM are shown in [Fig 3C](#pone.0232427.g003){ref-type="fig"}. There was no difference between the HCM groups, however, in both disease stages women showed significantly more fibrosis than men ([Fig 3B](#pone.0232427.g003){ref-type="fig"}). We found significant correlations between the degree of diastolic dysfunction and titin isoform composition ([Fig 3D](#pone.0232427.g003){ref-type="fig"}; R^2^: 0.13; p\<0.05) and the amount of fibrosis ([Fig 3E](#pone.0232427.g003){ref-type="fig"}; R^2^: 0.31; p\<0.01).

![Titin and Fibrosis--Female patients show more complaint titin isoform and fibrosis than male patients.\
A) Diseased hearts (n = 42) show an increase in titin N2BA/N2B ratio compared to controls (p\<0.05). The difference in titin composition is mainly attributed to the female patients, who show an increase in compliant titin compared to male patients (p\<0.05) and compared to controls (p\<0.01)(no sex-difference in N2BA/N2B ratio was present in the control group). B) Representative Picro-Sirius red stainings of HCM stage II and IV patient samples. C) The amount of fibrosis is depicted as collagen volume fraction (CVF). In comparison to controls, fibrosis is increased in the diseased hearts (stage II (n = 29) and stage IV HCM (n = 8), p\<0.001). Female patients show higher levels of fibrosis compared to male patients (p\<0.05). Significant correlations were found between the N2BA/N2B ratio and grade of diastolic dysfunction (p\<0.05; panel E), and fibrosis and diastolic function (p\<0.05; panel F). Blue dots and squares depict stage IV HCM patients. Controls used for titin isoform analysis: 1--3, 5--6, 8, 10, 13--14, 16, 20, 22, 24, 26--27. Controls used for the amount of fibrosis: 4, 8--10, 21, 23, 26, 29--30.](pone.0232427.g003){#pone.0232427.g003}

[Fig 4A](#pone.0232427.g004){ref-type="fig"} shows images of capillary staining in a stage II and IV HCM sample. Capillary density is depicted as capillaries per mm^2^ ([Fig 4B](#pone.0232427.g004){ref-type="fig"}) as well as per cardiomyocyte ([Fig 4C](#pone.0232427.g004){ref-type="fig"}). Capillary density is significantly lower in stage II and IV HCM patients compared to controls ([Fig 4B and 4C](#pone.0232427.g004){ref-type="fig"}; p\<0.0001). Furthermore, both methods showed a lower capillary density in stage IV compared to stage II HCM patients (p\<0.05). Capillary density in stage II HCM is significantly lower in women compared to men (p\<0.05). Interestingly, the reduction in capillary density from stage II to stage IV is attributed to the reduction of capillary density in male to a similar level as observed in female HCM patients.

![Capillary density--decreased capillary density in HCM patients.\
A) Representative CD31 staining of HCM stage II and IV samples are shown. B) Capillary density is depicted as the number of capillaries per mm^2^. Capillary density is decreased in HCM stage II (n = 22) and stage IV (n = 8) compared to controls (p\<0.0001). The change in capillary density is sex-dependent. Female patients show lower capillary density compared to male patients (p\<0.05). C) Capillary density is depicted as the number of capillaries per cardiomyocyte. Capillary density is decreased in HCM patients compared to controls (p\<0.05). Capillary density is significantly decreased in stage IV compared to stage II male patients (p\<0.05). Blue dots and squares represent stage IV HCM patients. Controls used for capillary density: 8--9, 21, 23, 25--26, 29--30.](pone.0232427.g004){#pone.0232427.g004}

Discussion {#sec010}
==========

We investigated if cardiac tissue properties were more severely affected at stage IV (end-stage) than stage II of HCM, and whether these properties change in a sex-specific manner. The main findings of our study are: 1) Changes in (functional) myofilament properties of cardiomyocytes are similar in stage II and stage IV HCM; 2) A similar increase in fibrosis compared to controls is present at stage II and IV HCM; 3) Capillary density is significantly lower at stage IV compared to stage II HCM; 4) Sex-specific differences in HCM are marked by higher levels of fibrosis, a larger shift to compliant titin isoform and a lower capillary density in female compared to male patients; 5) The disease-stage specific decrease in capillary density is largely explained by the lower capillary density in men at stage IV compared to stage II. Overall, our study indicates that loss of capillary density may be a factor underlying disease progression from stage II to IV in HCM.

Age at time of operation (myectomy or heart transplantation) did not differ between the two HCM groups and is in line with previous studies.\[[@pone.0232427.ref010],[@pone.0232427.ref024],[@pone.0232427.ref025]\] HCM onset at a young age is one of the risk factors for developing stage IV HCM. Furthermore, HCM patients that progress to stage IV more often experience atrial fibrillation, mitral valve regurgitation, more symptom progression and less LVOTO.\[[@pone.0232427.ref024],[@pone.0232427.ref026]\] Many stage IV patients did not have surgical myectomy before heart transplantation, probably due to the lower frequency of LVOTO in these patients.\[[@pone.0232427.ref024]\] Because stage IV patients reach phase II of HCM at a younger age and progress faster, their age at heart transplantation is similar to HCM patients who undergo surgical myectomy.

As expected, cardiac remodeling was different between stage II and IV HCM patients ([Table 2](#pone.0232427.t002){ref-type="table"}). Stage IV patients show less hypertrophy of the IVS and increased dimensions of both LV and left atrium.\[[@pone.0232427.ref008]\] Both our patient groups showed a predominance of the male sex (stage II: 56% and stage IV: 60%) which is in line with earlier research (ranging from 55--72% in end-stage HCM).\[[@pone.0232427.ref025]--[@pone.0232427.ref030]\] As for stage II HCM patients, based on our recent study, we have proposed that women may be diagnosed too late because the cut-off value for IVS is not corrected by body surface area.\[[@pone.0232427.ref015]\] The latter may partly explain the predominance of male patients in our HCM groups. Interestingly we did find a difference in drug regimen between stage II women and men. The most prescribed drugs in both genders were betablockers, calcium channel blockers or a combination of both. Men were commonly prescribed betablockers (80% in men versus 58% in women), while women were more frequently prescribed calcium channel blockers (58% versus 27%) and dual therapy (38% versus 20%).

The main difference identified between early and end-stage HCM patient groups was the larger reduction in capillary density in stage IV compared to stage II. It is known that myocardial blood flow is decreased in HCM patients, with greatest impairments seen during hyperemic circumstances.\[[@pone.0232427.ref031]\] The IVS and sub-endocardial layers are particularly hypo perfused.\[[@pone.0232427.ref032],[@pone.0232427.ref033]\] Importantly, reduced myocardial blood flow has been associated with fibrotic areas of the myocardium.\[[@pone.0232427.ref032]\] Chronic exposure to ischemia, whether due to coronary occlusion or the inability to properly vascularize the hypertrophied myocardium (decreased capillary density),\[[@pone.0232427.ref005],[@pone.0232427.ref034]\] leads to necrosis, massive fibrosis and eventually wall thinning.\[[@pone.0232427.ref026],[@pone.0232427.ref035]\] Microvascular dysfunction in HCM patients was associated with a higher incidence of end-stage heart failure.\[[@pone.0232427.ref032],[@pone.0232427.ref036]\] The lower capillary density in stage IV compared to stage II HCM patients indicates that reduced coronary perfusion plays a role in disease progression from HCM to end-stage heart failure.

We are the first to report a sex-difference in capillary density in stage II HCM patients, where woman have lower capillary density compared to men. Previous reports that analyzed capillary density have found no influence of sex but were not performed in HCM patients.\[[@pone.0232427.ref037]--[@pone.0232427.ref041]\] A recent study showed a correlation between microvascular density and fibrosis, in which a decrease in capillary density was correlated with an increase in fibrosis.\[[@pone.0232427.ref037]\] Furthermore, parameters of diastolic dysfunction were negatively associated with microvascular density.\[[@pone.0232427.ref037]\] Interestingly, a significant decrease in capillary density was found only in male patients between HCM stage II and IV. Capillary density in men with stage IV HCM decreased to the level of women with HCM. It has been reported that myocardial blood flow in women at rest is higher compared to men, while the flow reserve (ie. increase in myocardial blood flow between rest and stress) is lower in women.\[[@pone.0232427.ref042]--[@pone.0232427.ref044]\] In addition, a correlation was found between myocardial blood flow and diastolic dysfunction in women.\[[@pone.0232427.ref042]\] Furthermore, endothelial cell response may be impaired and contribute to HCM disease progression. Future studies are warranted to define the cellular components which underlie perturbations in myocardial blood flow during HCM disease progression.

Titin is known to modulate passive stiffness of the cardiomyocyte in an isoform-dependent manner as it functions as a molecular spring.\[[@pone.0232427.ref032]\] The heart consists of two isoforms, a short and stiff N2B isoform and a longer more compliant N2BA isoform. Titin-based stiffness can therefore be displayed as the N2BA/N2B isoform ratio. Our previous study\[[@pone.0232427.ref015]\] showed a larger shift to more compliant titin isoform in female compared to male stage II HCM patients, which coincided with a higher level of fibrosis. This is in line with the suggestion that the increased titin compliance might be an attempt to compensate for the increased fibrosis and diastolic dysfunction. Our current study shows that titin isoform composition is not altered during disease progression as a similar pattern is seen at stage IV HCM ([Fig 3A](#pone.0232427.g003){ref-type="fig"}). In accordance, the passive force measurement curves of both HCM groups clearly overlap ([Fig 2B](#pone.0232427.g002){ref-type="fig"}), indicating that passive properties of myofilaments are not altered during HCM disease progression.

All of our patients that underwent myectomy were labeled as stage II HCM. Our previous and current study indicate that tissue remodeling is more advanced in women than in men at an earlier (stage II) disease stage, i.e. more fibrosis, a change in titin isoform composition and a reduction in capillary density. Based on our observations, our HCM stage II women may actually be at a more advanced disease stage and may be in need of a more aggressive treatment.

Clinical perspectives and relevance {#sec011}
===================================

What is new? {#sec012}
------------

Since no differences were observed in cardiomyocyte contractile properties between early and advanced stage of HCM, our study points to microvascular ischemia and fibrosis as main mechanisms of disease progression rather than cardiomyocyte dysfunction. This suggests that similar molecular therapeutic targets may be at play in all phases of HCM within the myocardium, and that the different clinical profiles are mostly due to extra-cardiomyocyte variations.

What are the clinical implications? {#sec013}
-----------------------------------

Analyses of coronary perfusion may be warranted in HCM patients who show a reduction in IVS during regular clinical check-ups to identify HCM patients at risk to develop end-stage heart failure.

Translational outlook {#sec014}
=====================

Capillary density is only one component of microvascular dysfunction, together with loss of small vessel vasodilatory function and vessel compression due to increased wall stress. Future research could focus on evidence of ischemia and clinical research regarding small vessel function.

Supporting information {#sec015}
======================

###### Controls.

Abbreviations: F (female); M (male).

(DOCX)

###### 

Click here for additional data file.

We would like to give special thanks to Maike Schuldt who has helped with the embedding of cardiac tissue. Furthermore, we appreciate the technical contribution of Elisa Meinster, Ruud Zaremba and Wies Lommen. We would like to thank Vasco Sequeira for the design of [Fig 1B](#pone.0232427.g001){ref-type="fig"}.

10.1371/journal.pone.0232427.r001

Decision Letter 0

Gomes

Aldrin V.

Academic Editor

© 2020 Aldrin V. Gomes

2020

Aldrin V. Gomes

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

12 Feb 2020

PONE-D-20-01193

Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy

PLOS ONE

Dear Ms Nijenkamp,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address the reviewers comments and pay attention to the punctuation, spelling and grammar in the text of the manuscript.

We would appreciate receiving your revised manuscript by Mar 28 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Aldrin V. Gomes, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for including your ethics statement:

The study protocol was approved by the local Ethics Committees, and written consent was obtained.

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

3\. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. \[\"part of the stage II HCM data has been part of a manuscript which was published in Circulation Heart Failure\"\] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

4\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1) The abstract should clearly represent the rationale and snapshot of the methods used. It must be reorganized and rewrite

2\) Common punctuation, spelling and grammar mistake throughout the manuscript

3\) The method section is too concise needs elaboration in terms of approaches used for the study. Additionally, vendor/manufacturer information should be reported in an eligible scientific fashion.

4\) In both results and figure legends, the inference of data should be shifted to the discussion section.

5\) In figure 3D, regarding diastolic dysfunction measurement, functional data/grading parameters are not provided in the manuscript. Table 1 only provides dimension-based data.

Reviewer \#2: The manuscript by Nijenkamp and colleagues sought to assess cardiomyocyte contractile and cardiac muscle tissue properties from a subset of male and female HCM patients that progress to severe end-stage HCM to identify factors underlying the transition from stable stage II to progressive stable IV HCM. Overall, this is a well-executed study that specifically exploits a defined cohort of HCM patients to better dissect whether defects in contractile properties precede the structural destruction of cardiac muscle in HCM in a patient context. The authors suggest that HCM disease progression does not correlate with contractile muscle deficits, but instead titin muscle compliance, fibrosis and capillary density, which may also be impacted in a sex-specific manner. Comments are included to strengthen the manuscript.

Minor Comments:

1\. It would be helpful if the authors would diagram the mutations (in Figure 1) in the context of domains of each protein as it may provide broad overview as to which mutations may be the most deleterious or pathogenic (or whether there is clustering of mutations at a specific domain).

2\. It is not clear what is significant and which groups are being compared in Figure 3A and Figure 4A for significance. If possible, representative images from blots should be shown to highlight male versus female differences in each of these contexts with controls shown.

3\. It would be helpful to note and discuss drug regimen (length of time on drug regimens) of HCM patients in these cohorts as it may impact readouts when assessing progression of HCM in these patients (eg., fibrosis, etc.)

4\. The authors should clarify and include the contribution of titin isoform switch in their discussion to suggest its potential importance in sex differences as it is shown in their data (Figure 3A).

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232427.r002

Author response to Decision Letter 0

28 Mar 2020

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We have formatted the title page to meet the requirements of PLOS ONE. All Figure citations have been changed and figures have been uploaded as .tif files. Supporting Tables have now been submitted in separate files and a list of supporting information has been added to the manuscript. Citations have been formatted to Vancouver style with brackets.

2\. Thank you for including your ethics statement: The study protocol was approved by the local Ethics Committees, and written consent was obtained.

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

We have added the full name of the METC in brackets:

This study was approved by the local ethics board of the Erasmus Medical Center (protocol number MEC-2010-40) and written informed consent of patients was obtained. Non-failing donor samples were acquired from the University of Sydney, Australia, with the ethical approval of the Human Research Ethics Committee (\#2012/2814).

3\. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. \[\"part of the stage II HCM data has been part of a manuscript which was published in Circulation Heart Failure\"\] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

As stated in our cover letter, this publication has been published in Circulation Heart Failure (2018). At first submission we have uploaded a copy of this paper. It was peer-reviewed and this work does not constitute dual publication. Some patients in the stage II HCM group have been included in both our previous study and in this manuscript. For this manuscript we have added more patients to the stage II HCM group in line with our expanding biobank. In addition to our previous study, we studied capillary density which we believe may play a central role in HCM disease progression.

Due to our expanding biobank we have recently started to use our sample codes in published papers to give a clear overview of the samples that are included in each study. This is why we have now updated our table (Table 1) with the biobank sample codes. In the future this will increase transparency and comparison between studies.

4\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

We have included captions for our Supporting Information files at the end of our manuscript, and have updated in-text citations to match accordingly.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

3\. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer \#1: No

Reviewer \#2: Yes

We believe the data reviewer \#1 is referring to is now displayed in total in our Supporting information files.

 

Reviewer \#1:

1\) The abstract should clearly represent the rationale and snapshot of the methods used. It must be reorganized and rewrite

As requested we have rewritten the abstract, which now includes the rational and details of the methods:

Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease with a prevalence of 1:500 to 1:200. While most patients show obstructive HCM and a relatively stable clinical phenotype (stage II), a small group of patients progresses to end-stage HCM (stage IV) within a relatively brief period. Previous research showed sex-differences in stage II HCM with more diastolic dysfunction in female than in male patients. Moreover, female patients more often show progression to heart failure. Here we investigated if differences in functional and structural cardiac properties may underlie sex-differences in disease progression from stage II to stage IV HCM. Cardiac tissue from stage II and IV patients was obtained during myectomy (n=54) and heart transplantation (n=10), respectively. Isometric force was measured in membrane-permeabilized cardiomyocytes to define active and passive myofilament force development. Titin isoform composition was assessed using gel electrophoresis, and the amount of fibrosis and capillary density were determined with histology. In accordance with disease stage-dependent adverse cardiac remodeling end-stage failing patients showed a thinner interventricular septal wall and larger left ventricular and atrial diameters compared to stage II patients. Cardiomyocyte contractile properties and fibrosis were comparable between stage II and IV, while capillary density was significantly lower in stage IV compared to stage II. Women showed more adverse cellular remodeling compared to men at stage II, evident from more compliant titin, more fibrosis and lower capillary density. However, the disease stage-dependent reduction in capillary density was largest in men. In conclusion, the more severe cellular remodeling in female compared to male stage II patients suggests a more advanced disease stage at the time of myectomy in women. Changes in cardiomyocyte contractile properties do not explain the progression of stage II to stage IV, while reduced capillary density may underlie disease progression to end-stage heart failure.

2\) Common punctuation, spelling and grammar mistake throughout the manuscript

We have subjected our manuscript to a spelling and grammar control. Furthermore we have asked a native English speaker to carefully read the paper and adjusted the text of the revised manuscript.

3\) The method section is too concise needs elaboration in terms of approaches used for the study. Additionally, vendor/manufacturer information should be reported in an eligible scientific fashion.

We have divided our methods section in subheadings and added a new paragraph: Echocardiographic measurements, including two new references.

Further details of our methods can be found in the referenced articles in our methods section.

Echocardiographic measurements

Echocardiographic studies were done with commercially available systems and analyzed according to the American Society of Echocardiography guidelines.\[16\] Maximal wall thickness, left atrial diameter (LAD), LV end-diastolic diameter (LVEDD), and LVOTO gradient were measured. LVOTO was defined as a gradient ≥ 30 mmHg at rest or during provocation. Mitral valve inflow was recorded using pulsed wave Doppler from the apical four chamber view. Mitral E and A velocity (cm/s) and deceleration time (ms) were measured. Pulsed wave tissue Doppler imaging was used to measure septal e' velocity (cm/s). Continuous wave Doppler in the parasternal and apical four chamber was used to measure tricuspid regurgitation (TR) velocity (m/s). Echocardiographic data and medication are shown in Table 1. For the end-stage HCM group, a limited set of echocardiographic data was obtained, and not all parameters were obtained for stage II patients.

Diastolic dysfunction was graded as follows: grade I when E/A ratio ≤ 0.8 and E peak velocity ≤ 50 cm/s; grade III when E/A ratio ≥ 2. In patients with E/A ratio ≤ 0.8 and E peak velocity \> 50 cm/s or E/A ratio \> 0.8 but \< 2, the E/e' ratio (\>14), LADi (\>24) and TR velocity (\> 2.8 m/s) were used to further differentiate diastolic function. When ≥ 2 out of 3 variables were abnormal, LA pressure was elevated and grade II diastolic dysfunction was present. When 1 out of 3 variables was abnormal, grade I diastolic dysfunction was present.\[17\]

16\. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, e.a. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2011;24(5):473--98.

17\. Nagueh SF, Smiseth OA, Appleton CP. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016(29):277--314.

Furthermore we have added a new reference to the following subheadings:

"Isometric force measurements" and "protein analyses"

19\. Bollen IAE, van der Meulen M, de Goede K, Kuster DWD, Dalinghaus M, van der Velden J. Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy. Front Physiol \[Internet\]. 2017

4\) In both results and figure legends, the inference of data should be shifted to the discussion section.

We have deleted or moved all discussion from the results and figure legends to the discussion (changes are indicated in the manuscript text).

5\) In figure 3D, regarding diastolic dysfunction measurement, functional data/grading parameters are not provided in the manuscript. Table 1 only provides dimension-based data.

We have added the echocardiographic parameters used in grading diastolic dysfunction (E/A ratio, e' velocity and TR velocity) to Table 1, and added the following text to the results section:

All stage IV patients were given grade III diastolic dysfunction, while stage II patients included 29% with grade III, 29% with grade II and 42% with grade I diastolic dysfunction. Female stage II patients show more severe diastolic dysfunction compared to male patients: 86% grade II or III diastolic dysfunction in women compared to 42% grade II in men.

Reviewer \#2: The manuscript by Nijenkamp and colleagues sought to assess cardiomyocyte contractile and cardiac muscle tissue properties from a subset of male and female HCM patients that progress to severe end-stage HCM to identify factors underlying the transition from stable stage II to progressive stable IV HCM. Overall, this is a well-executed study that specifically exploits a defined cohort of HCM patients to better dissect whether defects in contractile properties precede the structural destruction of cardiac muscle in HCM in a patient context. The authors suggest that HCM disease progression does not correlate with contractile muscle deficits, but instead titin muscle compliance, fibrosis and capillary density, which may also be impacted in a sex-specific manner. Comments are included to strengthen the manuscript.

Minor Comments:

1\. It would be helpful if the authors would diagram the mutations (in Figure 1) in the context of domains of each protein as it may provide broad overview as to which mutations may be the most deleterious or pathogenic (or whether there is clustering of mutations at a specific domain).

We have added a new column to Table 1 which states the domains of the mutations. Furthermore we have added a new figure (Fig 1B) that displays the structure of the proteins myosin heavy chain, myosin binding protein-C and cardiac troponin T. We have introduced blue flags to highlight the location of the mutations.

The following text has been added to the manuscript:

Fig 1A illustrates the different gene mutations and Fig 1B shows where mutations are located in the protein. Table 1 provides an overview of the gene mutations of all patients.

We have added the following legend to our new figure:

Fig 1B. Mutation location.

Schematic of 3 main HCM sarcomere proteins: myosin heavy chain in green (Myosin), cardiac myosin-binding protein-C in purple (cMyBP-C) and cardiac troponin T in orange (cTnT). The location of the mutations is indicated with the blue circles (M). The letters N and C stand for the N-terminus and C-terminus respectively. The numbers indicate the amino acids of the sarcomere proteins.

2\. It is not clear what is significant and which groups are being compared in Figure 3A and Figure 4A for significance. If possible, representative images from blots should be shown to highlight male versus female differences in each of these contexts with controls shown.

As stated in the methods section (now under subheading: data analyses) differences to controls are indicated by an asterisk (\*), sex-differences are indicated by a hashtag (\#).

Fig 3A: there is a significant difference between HCM samples and control samples; and there is a significant difference between HCM men and HCM women. This has also been stated in the figure legend:

A\) Diseased hearts (n=42) show an increase in titin N2BA/N2B ratio compared to controls (p\<0.05). The difference in titin composition is mainly attributed to the female patients, who show an increase in compliant titin compared to male patients (p\<0.05) and compared to controls (p\<0.01)(no sex-difference in N2BA/N2B ratio was present in the control group).

Fig 4A shows CD31 staining of stage II and IV HCM patients. When capillary density is measured per mm2 (Fig 4B) there is a significant decrease in HCM patients compared to controls; and a significant lower density in HCM women compared to HCM men (which is stated in the figure legend).

When capillary density is measured per cardiomyocyte there is a significant decrease in stage IV HCM men compared to stage II HCM men (stated in the figure legend).

3\. It would be helpful to note and discuss drug regimen (length of time on drug regimens) of HCM patients in these cohorts as it may impact readouts when assessing progression of HCM in these patients (eg., fibrosis, etc.)

We have obtained the drug regimen of 73% of our study population. We were able to obtain drug regimen at the time of surgery. Unfortunately, we were not able to obtain duration of drug regimen. We have added the new information to Table 1, which shows the drug use per patient at the time of operation. 61% of all patients used betablockers and 34% used calcium channel blockers. Of all patients 23% use both betablockers and calcium channel blockers. It is hard to make a comparison between stage II and stage IV HCM because we only have the drug regimen of 1 patient in the stage IV HCM group.

We have added the following text in the Results section:

Drug regimen was different between female and male stage II HCM patients: 80% of the men received betablockers in contrast to 58% of the women. Calcium channel blockers were prescribed more frequently to women compared to men (58% versus 27%, respectively; Table 1). Unfortunately we could only retrieve drug regimen of one of our stage IV patients.

We added the following text to the discussion:

Interestingly we did find a difference in drug regimen between stage II women and men. The most prescribed drugs in both genders were betablockers, calcium channel blockers or a combination of both. Men were commonly prescribed betablockers (80% in men versus 58% in women), while women were more frequently prescribed calcium channel blockers (58% versus 27%) and dual therapy (38% versus 20%).

4\. The authors should clarify and include the contribution of titin isoform switch in their discussion to suggest its potential importance in sex differences as it is shown in their data (Figure 3A).

As requested we have added a paragraph to the discussion:

Titin is known to modulate passive stiffness of the cardiomyocyte in an isoform-dependent manner as it functions as a molecular spring.\[32\] The heart consists of two isoforms, a short and stiff N2B isoform and a longer more compliant N2BA isoform. Titin-based stiffness can therefore be displayed as the N2BA/N2B isoform ratio. Our previous study\[15\] showed a larger shift to more compliant titin isoform in female compared to male stage II HCM patients, which coincided with a higher level of fibrosis. This is in line with the suggestion that the increased titin compliance might be an attempt to compensate for the increased fibrosis and diastolic dysfunction. Our current study shows that titin isoform composition is not altered during disease progression as a similar pattern is seen at stage IV HCM (Fig 3A). In accordance, the passive force measurement curves of both HCM groups clearly overlap (Fig 2B), indicating that passive properties of myofilaments are not altered during HCM disease progression.
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